Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care
Open accessThe DOI matches its Crossref record; 53 of the 55 references it cites were found in a registry or an index, and 2 are not checked yet.
Abstract
Background: The aim of the study was to determine the most common treatment strategies and their costs for patients with an inadequate response to first-line antidepressant treatment (AD) in primary care. Method: A retrospective cohort study of medical records from six primary care centers was conducted. Adults with a major depressive disorder diagnosis, at least 8 weeks of AD treatment after the first prescription, and patient monitoring for 12 months were analyzed. Healthcare (direct cost) and non-healthcare costs (indirect costs; work productivity losses) were described. Results: A total of 2,260 patients were studied. Forty-three percent of patients (N = 965) presented an inadequate response to treatment. Summarizing the different treatment approaches: 43.2% were switched to another AD, 15.5% were given an additional AD, AD dose was increased in 14.6%, and 26.7% remained with the same antidepressant agent. Healthcare/annual costs were 451.2 Euros for patients in remission vs. 826.1 Euros in those with inadequate response, and productivity losses were 991.4 versus 1,842.0 Euros, respectively (p < 0.001). Conclusion: Antidepressant switch was the most common therapeutic approach performed by general practitioners in naturalistic practice. A delay in treatment change when no remission occurs and a significant heterogeneity in management of these patients were also found.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, the treatment of patients with TRD is associated with an increase in healthcare resource utilization (HCRU) and economic cost, due to a higher number of visits to both primary and secondary care practitioners, a higher rate of hospitalizations, and more psychiatric prescriptions including anxiolytics, hypnotics and antipsychotics 17,19,20 .”
From A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom (2021) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 2×
“Patients were considered to be in remission when they had a Hamilton Depression Rating Scale total score ≤ 7 points after at least 8 weeks of AD treatment in adequate doses [24,25].”
MethodAnderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908 · cited 2×
“depressive episodes, a shorter duration between episodes, and a worse functioning [8,13-16].”
BackgroundRush, A. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1905 · Cited by 870 · cited 2×
“The STAR-D study showed that patients with longer depressive episodes were less likely to achieve remission [46].”
BackgroundHow should cost data in pragmatic randomised trials be analysed?
Thompson, S. G. (2000) · BMJ · doi:10.1136/bmj.320.7243.1197 · Cited by 772 · cited 1×
“Cost comparison was performed in accordance to recommendations by Thompson and Barber, specifically on the comparison of average health care cost between the study groups [32].”
MethodHess, L. M., Raebel, M. A., Conner, D. A., & Malone, D. C. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h018 · Cited by 756 · cited 1×
“Our results are clearly higher, possibly because of the indirect measurement method used [36].”
ResultKennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Research works printed but not linked: 1
- Johns Hopkins Bloomberg School of Public Health: The Johns Hopkins ACG® Case-mix System version 7.0-April, 2005. 2005, Baltimore
Cited by
Saveanu, R., Etkin, A., Duchemin, A.-M., Goldstein-Piekarski, A., Gyurak, A., Debattista, C., Schatzberg, A. F., Sood, S., Day, C. V. A., Palmer, D. M., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.12.018 · Cited by 151
Cost of Disorders of the Brain in Spain
Parés-Badell, O., Barbaglia, G., Jerinic, P., Gustavsson, A., Salvador-Carulla, L., & Alonso, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105471 · Cited by 100
Economic impact of treatment-resistant depression: A retrospective observational study
Pérez-Sola, V., Roca, M., Alonso, J., Gabilondo, A., Hernando, T., Sicras-Mainar, A., Sicras-Navarro, A., Herrera, B., & Vieta, E. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.08.036 · Cited by 55
Self-citationYoung, A. H., Evitt, L., Brignone, M., Diamand, F., Atsou, K., Campbell, R., Cure, S., & Danchenko, N. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.019 · Cited by 15
“Patients who have encountered multiple episodes or multiple lines of treatment are at a 13 greater risk of suicide attempts (5), hospital admissions (6), and impaired work productivity (7).”
BackgroundDenee, T., Ming, T., Waller, J., Bailey, T., Rajkovic-Hooley, O., Middleton-Dalby, C., Le, H. H., Zhang, Q., McCrone, P., & Taylor, D. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1857580 · Cited by 12
Metadata
- Authors
- Sicras-Mainar, A., Maurino, J., Cordero, L., Blanca-Tamayo, M., & Navarro-Artieda, R.
- Affiliations
- AstraZeneca (Spain) (ES)
- Badalona Serveis Assistencials (ES)
- Venue
- Annals of General Psychiatry
- Published
- 2012-08-03
- Volume
- 11
- Issue
- 1
- Pages
- 22-22
- ISSN
- 1744-859X (ISSN-L)
- PMC
- PMC3426459
- OpenAlex
- W2110135544
- Cited by
- 11
- References
- 54
- Citations by year
- 2022: 1 · 2021: 1 · 2020: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 3
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Annals of General Psychiatry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- major depressive disorder, inadequate response to antidepressants, antidepressant switching, antidepressant augmentation, dose escalation, treatment costs, health care costs, indirect costs, work productivity loss, primary care, general practitioners, treatment options
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care. https://app.cochat.ai/papers/10.1186/1744-859x-11-22
- The paper
- Sicras-Mainar, A., Maurino, J., Cordero, L., Blanca-Tamayo, M., & Navarro-Artieda, R. (2012). Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care. Annals of General Psychiatry. https://doi.org/10.1186/1744-859x-11-22
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

